Clinical Trial Update: Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study [Phase 2]

View source ↗

Summary

This open-label, single-arm Phase II trial evaluates the safety and potential efficacy of combining oral etoposide with Anlotinib and Envafolimab as first-line …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Envafolimab (envafolimab)
• Etoposide (oral) (etoposide)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Progression Free Survival(PFS) | Phase 2 | Status: ACTIVE_NOT_RECRUITING